Acrivon Therapeutics, Inc. (NASDAQ: ACRV), a clinical stage biopharmaceutical company with a market capitalization of $184 million and an impressive 60% stock return over the past year, announced that ...

Acrivon Therapeutics said the Food and Drug Administration has granted Breakthrough Device designation for its ACR-368 OncoSignature assay, an immunofluorescence assay for the identification of ...

The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ...

An understanding has been agreed to drop a provision that would have caused the collapse of private medical-insurance ...

Cristina Brennan can hear the clock ticking. At the end of the year, her 12-year-old son Tristan will no longer have free ...

A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, potentially improving survival and expanding treatment options. A novel approach ...

In an era where self-care is paramount, and people are veering away from invasive and chemical-heavy treatments, GFC emerges ...

People living with inflammatory bowel disease (IBD) have new hope, with clinical trials beginning for a breakthrough treatment for one of the most ...

Researchers at University of the Pacific in Stockton have developed a long-acting opioid overdose-reversal drug-delivery system that could save lives.

Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice. The novel drug CT-179 was ...

Brain cancer is the second-leading cause of death in children in the developed world. For the children who survive, standard ...